TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31095562

Group type: EXPERIMENTAL
Intervention: Induced pain
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral
Number of subjects: 0
Study: 28317828

Group type: EXPERIMENTAL
Intervention: magnetic therapy for 5 min №10 in maxillary and mandibular areas
Number of subjects: 60

Group type: COMPARATOR
Intervention: impulse carbonate irrigation for 12 min №10
Number of subjects: 60
Study: 25544113

Group type: COMPARATOR
Intervention: Iron alone (5mg as FeSO4)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Iron with phytic acid (10mg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Iron with tannic acid (100mg)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Iron with citrus pectin (250mg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Iron alone with calcium (800mg CaCl2)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Iron with phytic acid and calcium
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Iron with tannic acid and calcium
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Iron with citrus pectin and calcium
Number of subjects: 28
Study: 23685999

Group type: EXPERIMENTAL
Intervention: Trabeculectomy surgery
Number of subjects: 122
Study: 21453706

Group type: EXPERIMENTAL
Intervention: LPS-treated samples
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated samples
Number of subjects: 0
Study: 19837362

Group type: EXPERIMENTAL
Intervention: HPV information presentation
Number of subjects: 0
Study: 16330466

Group type: EXPERIMENTAL
Intervention: Combination therapy (ramipril 5 mg/day + candesartan 8 mg/day)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Ramipril alone (10 mg/day)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Candesartan alone (16 mg/day)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (baseline urinary TGF-beta1 level)
Number of subjects: 21
Study: 15469418

Group type: EXPERIMENTAL
Intervention: N4311S polymorphism
Number of subjects: 1442

Group type: EXPERIMENTAL
Intervention: E4154K (EcoRI) polymorphism
Number of subjects: 1442

Group type: EXPERIMENTAL
Intervention: T2488T (XbaI) polymorphism
Number of subjects: 1442
Study: 10955239

Group type: EXPERIMENTAL
Intervention: Cefazopran (CZOP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Cefpirome (CPR)
Number of subjects: 80
Study: 9323778

Group type: EXPERIMENTAL
Intervention: Experimental group (structured dialogue focusing on concepts of pain)
Number of subjects: 92
Study: 8225636

Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg b.i.d. for 5 days
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg b.i.d. for 10 days
Number of subjects: 221

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 221
Study: 3081928

Group type: EXPERIMENTAL
Intervention: Diazepam 0.3 mg/kg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Oxazepam 1.2 mg/kg
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 30230257

Group type: EXPERIMENTAL
Intervention: Old drug product (DP)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: New drug product (DP)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Upper arm injection site
Number of subjects: 48

Group type: COMPARATOR
Intervention: Thigh injection site
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of emicizumab
Number of subjects: 48
Study: 29073803

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Arteriograph
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 71
Study: 27228052

Group type: EXPERIMENTAL
Intervention: Roux‐en‐Y gastric bypass (RYGB)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Lifestyle intervention
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 16
Study: 25004335

Group type: EXPERIMENTAL
Intervention: 0.5 mg oral estradiol per day
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: 75 mg venlafaxine per day
Number of subjects: 256

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study: 22918526

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 19826112

Group type: EXPERIMENTAL
Intervention: 31 oncology drugs approved without a randomized trial
Number of subjects: 79

Group type: COMPARATOR
Intervention: Gefitinib (EGFR inhibitor)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: 31 oncology drugs
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: 19 of the 31 drugs
Number of subjects: 79
Study: 17207470

Group type: EXPERIMENTAL
Intervention: Dietary intake of calories, carbohydrates, and fat
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Reported frequency of GI abnormalities
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Correlation of dietary intake with stool consistency
Number of subjects: 62
Study: 16120482

Group type: EXPERIMENTAL
Intervention: Sodium Valproate
Number of subjects: 120

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 120
Study: 12690666

Group type: EXPERIMENTAL
Intervention: Continuous dopaminergic stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pulsatile dopaminergic stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dopaminergic agonists
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Catechol‐O‐methyl transferase inhibitors
Number of subjects: 0
Study: 9522658

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) 1 g/kg
Number of subjects: 43

Group type: COMPARATOR
Intervention: Methylprednisolone (MPPT) 30 mg/kg
Number of subjects: 43
Study: 7652970

Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study: 2570086

Group type: EXPERIMENTAL
Intervention: Haloperidol decanoate (1.5 cc or 75 mg)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Fluphenazine decanoate (1 cc or 25 mg)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Haloperidol decanoate
Number of subjects: 72

Group type: COMPARATOR
Intervention: Fluphenazine decanoate
Number of subjects: 72
Study: 183591

Group type: EXPERIMENTAL
Intervention: 100 mg of prednisone on alternate days
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo tablets on alternate days
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Prednisone maintenance dosage after 2 years
Number of subjects: 13
Study: 31116017

Group type: EXPERIMENTAL
Intervention: Computer-based cognitive behavioral therapy
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Audio-based cognitive behavioral therapy
Number of subjects: 51

Group type: COMPARATOR
Intervention: Delayed treatment control condition
Number of subjects: 51
Study: 29901860

Group type: EXPERIMENTAL
Intervention: BGF MDI 320/14.4/10 μg
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: BFF MDI 320/10 μg
Number of subjects: 72

Group type: COMPARATOR
Intervention: BUD/FORM DPI 320/9-μg delivered dose
Number of subjects: 72
Study: 28598402

Group type: EXPERIMENTAL
Intervention: Carbohydrate mouth rinsing (CHO: 1.6 g/25 mL)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Caffeine mouth rinsing (CAF: 67 mg/25 mL)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Guarana mouth rinsing (GUA: 0.4 g/25 mL)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo mouth rinsing (PL)
Number of subjects: 24
Study: 25740807

Group type: EXPERIMENTAL
Intervention: Large-diameter deep anterior lamellar keratoplasty (L-DALK)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Standard deep anterior lamellar keratoplasty (S-DALK)
Number of subjects: 132
Study: 23620934

Group type: EXPERIMENTAL
Intervention: Acupoint Massage (AM)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Electroacupuncture (EA)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Number of subjects: 120
Study: 21339436

Group type: EXPERIMENTAL
Intervention: Computer-assisted decision support during trauma resuscitation
Number of subjects: 1171

Group type: COMPARATOR
Intervention: Baseline control group
Number of subjects: 1171
Study: 18076229

Group type: EXPERIMENTAL
Intervention: 15 minutes of lower-limb massage (M)
Number of subjects: 37

Group type: COMPARATOR
Intervention: 15 minutes of placebo ultrasound (PU)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Rest (R)
Number of subjects: 37
Study: 15856721

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 195

Group type: COMPARATOR
Intervention: Nortriptyline
Number of subjects: 195
Study: 12221214

Group type: EXPERIMENTAL
Intervention: Prowashonupana (PW) barley
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard barley (BZ) 594.35.e
Number of subjects: 10
Study: 10223231

Group type: EXPERIMENTAL
Intervention: 5-FU 2600 mg/m2 with LV 100 mg/m2 administered via a portable infusion pump over 24 hours once a week for 5 weeks
Number of subjects: 36
Study: 8552441

Group type: EXPERIMENTAL
Intervention: r‐HuEpo
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control
Number of subjects: 28
Study: 2695558

Group type: EXPERIMENTAL
Intervention: Argon laser trabeculoplasty (ALT)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Medical treatment (vascular medications)
Number of subjects: 35
Study: 343787

Group type: EXPERIMENTAL
Intervention: Vincamine containing formulation (Pervincamin forte retard or Pervincamin ampoules)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31504690

Group type: EXPERIMENTAL
Intervention: High water intake (2.5 L/d)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Low water intake (0.5 L/d)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Ad libitum (AL) water intake
Number of subjects: 75
Study: 28627913

Group type: EXPERIMENTAL
Intervention: Attentional retraining (AR)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 64
Study: 25710953

Group type: EXPERIMENTAL
Intervention: Biodentine
Number of subjects: 53

Group type: COMPARATOR
Intervention: Fuji IX GIC
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: CBCT
Number of subjects: 53

Group type: COMPARATOR
Intervention: PA radiographs
Number of subjects: 53
Study: 23449367

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 1335
Study: 21256094

Group type: EXPERIMENTAL
Intervention: Levamisole administered as a liniment
Number of subjects: 0
Study: 19483180

Group type: EXPERIMENTAL
Intervention: Bupropion SR 300 mg/day
Number of subjects: 195

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 195
Study: 16392147

Group type: EXPERIMENTAL
Intervention: 1,450-nm diode laser treatment with cryogen cooling spray, 4, 8, or 12 J/cm2, 3 treatments at 6-week intervals
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (untreated side of the body)
Number of subjects: 11
Study: 15646404

Group type: EXPERIMENTAL
Intervention: IVCD estimation by echocardiographic method (study group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Traditional method for dry weight adjustment (control group)
Number of subjects: 100
Study: 12685794

Group type: EXPERIMENTAL
Intervention: Conical transmucosal implants (Nobel Biocare AB), 3.75 mm large and at least 9 mm long, immediately loaded with an implant‐retained overdenture.
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard Brånemark implants (MK II; Nobel Biocare AB), 3.75 mm large and at least 10 mm long, immediately loaded with an implant‐retained overdenture.
Number of subjects: 10
Study: 9859076

Group type: EXPERIMENTAL
Intervention: Cefixime (400 mg/24 h in a single daily dose for 12 days)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Amoxicillin (1 g/8 h per os) plus netilmicin (4 mg/kg/24 h in a single intramuscular daily dose for 5 days)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Cefixime
Number of subjects: 126

Group type: COMPARATOR
Intervention: Amoxicillin plus netilmicin
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Cefixime and Amoxicillin plus netilmicin
Number of subjects: 126
Study: 7631301

Group type: EXPERIMENTAL
Intervention: Hemovasal (glycosaminoglycan) administered in 3 different i.m. doses as single injections
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Hemovasal (300 mg daily oral dose for one week)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 36

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 36
Study: 1974070

Group type: EXPERIMENTAL
Intervention: 25 mg alpidem
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 50 mg alpidem
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 1 mg lorazepam
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 752851

Group type: EXPERIMENTAL
Intervention: Vincristine, cyclophosphamide, methotrexate, and 5-fluorouracil after conventional curative treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31968279

Group type: EXPERIMENTAL
Intervention: Home-based evaluation of executive function (Home-MET)
Number of subjects: 160
Study: 31125767

Group type: EXPERIMENTAL
Intervention: SRP followed by 1x immediate application of aPDT and 2x subsequent applications of aPDT without SRP
Number of subjects: 40

Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 40
Study: 28518132

Group type: EXPERIMENTAL
Intervention: Videolaryngoscopy (VL)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Direct laryngoscopy (DL)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Direct laryngoscopy (DL) after crossover to VL
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Videolaryngoscopy (VL) after crossover from DL
Number of subjects: 100

Group type: COMPARATOR
Intervention: Direct laryngoscopy (DL) before crossover to VL
Number of subjects: 100
Study: 25924679

Group type: EXPERIMENTAL
Intervention: CKD stages 1-3B (without diabetes or vascular disease)
Number of subjects: 7246

Group type: EXPERIMENTAL
Intervention: CKD stage 5 (not on dialysis)
Number of subjects: 7246

Group type: EXPERIMENTAL
Intervention: Maintenance dialysis
Number of subjects: 7246

Group type: EXPERIMENTAL
Intervention: Functioning kidney transplant
Number of subjects: 7246

Group type: EXPERIMENTAL
Intervention: Non-fatal major vascular events (for patients on dialysis)
Number of subjects: 7246

Group type: EXPERIMENTAL
Intervention: Non-fatal major vascular events (for patients not on dialysis)
Number of subjects: 7246
Study: 24018896

Group type: COMPARATOR
Intervention: CAB algorithm
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: ABC algorithm
Number of subjects: 108
Study: 21336855

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (intraperitoneal cisplatin, postoperative intravenous cisplatin, 5-fluorouracil, and daily oral FU (UFT) for 12 months)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 268
Study: 18471914

Group type: EXPERIMENTAL
Intervention: Postmastectomy radiotherapy
Number of subjects: 1000
Study: 17384492

Group type: EXPERIMENTAL
Intervention: Sonography for diagnosis and postoperative follow-up
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Sonography
Number of subjects: 26

Group type: COMPARATOR
Intervention: Nerve conduction studies
Number of subjects: 26
Study: 15563708

Group type: EXPERIMENTAL
Intervention: Individualised unsupervised home based exercise programme (3 sessions per week)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (no exercise programme)
Number of subjects: 48
Study: 11482465

Group type: EXPERIMENTAL
Intervention: Decompression of the posterior interosseous nerve (PIN)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Lengthening of the distal tendon of the extensor carpi radialis brevis (ECRB)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Overall outcome after a mean follow-up of 31 months
Number of subjects: 28
Study: 9783935

Group type: EXPERIMENTAL
Intervention: 0.4 mg tamsulosin
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: 0.8 mg tamsulosin
Number of subjects: 735
Study: 7870010

Group type: EXPERIMENTAL
Intervention: Serum TPA values
Number of subjects: 100
Study: 2974263

Group type: EXPERIMENTAL
Intervention: procaterol 0.05 mg twice daily for 2 wk followed by 0.10 mg twice daily for 10 wk
Number of subjects: 223

Group type: COMPARATOR
Intervention: albuterol 2 mg three times a day for 2 wk followed by 4 mg three times a day for 10 wk
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: procaterol
Number of subjects: 223

Group type: COMPARATOR
Intervention: albuterol
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: procaterol and albuterol
Number of subjects: 223
Study: 30530121

Group type: EXPERIMENTAL
Intervention: Oral β‐blocker therapy
Number of subjects: 10000

Group type: COMPARATOR
Intervention: No β‐blocker therapy
Number of subjects: 10000
Study: 29534639

Group type: EXPERIMENTAL
Intervention: Sunitinib as an adjunct to standard therapy (leucovorin, 5-fluorouracil, and irinotecan)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo as an adjunct to standard therapy (leucovorin, 5-fluorouracil, and irinotecan)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard therapy (leucovorin, 5-fluorouracil, and irinotecan)
Number of subjects: 52
Study: 26467679

Group type: EXPERIMENTAL
Intervention: Fluoride varnish (FV)
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Oral health promotion (OHP) activities
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Parent participation
Number of subjects: 518
Study: 24457412

Group type: EXPERIMENTAL
Intervention: Rhinovirus infection
Number of subjects: 25
Study: 22057424

Group type: EXPERIMENTAL
Intervention: β-glucan-enriched beverage (3 g barley β-glucan)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Fruit-based beverage (2.5 g dietary fibre)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (without dietary fibre)
Number of subjects: 14
Study: 21200103

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 50

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Levosimendan and Dobutamine
Number of subjects: 50
Study: 17374316

Group type: EXPERIMENTAL
Intervention: Efalizumab 1 mg/kg weekly for 12 weeks
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study: 15838685

Group type: EXPERIMENTAL
Intervention: Casein hydrolysate (Nutramigen; Mead Johnson)
Number of subjects: 242

Group type: COMPARATOR
Intervention: Conventional cow's milk-based formula
Number of subjects: 242
Study: 12181364

Group type: EXPERIMENTAL
Intervention: Moderate intensity exercise
Number of subjects: 140

Group type: COMPARATOR
Intervention: Reference group (control)
Number of subjects: 140
Study: 10460557

Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 35

Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 35
Study: 7598055

Group type: EXPERIMENTAL
Intervention: Diet with energy density of 1.67, 2.93, 4.18, or 6.28 kJ/g fed ad libitum three, four, or five times per day
Number of subjects: 18
Study: 2220978

Group type: EXPERIMENTAL
Intervention: 200,000 IU of oral vitamin A
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 619324

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil plus melphalan (5-FU + Melphalan)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Combination chemotherapeutic agents (ACFUME, ACFUCY)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: ACFUME and ACFUCY combinations
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Complete response patients
Number of subjects: 57
Study: 31028057

Group type: EXPERIMENTAL
Intervention: Indinavir (10 μM)
Number of subjects: 8
Study: 30220280

Group type: EXPERIMENTAL
Intervention: Insulin caliper for blood glucose control
Number of subjects: 92

Group type: COMPARATOR
Intervention: Conventional group (paper-based insulin dose modification scheme)
Number of subjects: 92
Study: 27217097

Group type: EXPERIMENTAL
Intervention: High-purity plasma-derived factor X concentrate (pdFX) administered preoperatively to raise FX:C to 70-90 IU dL(‐1) and postoperatively to maintain levels >50 IU dL(‐1) until no longer at risk of bleeding due to surgery.
Number of subjects: 5
Study: 24161781

Group type: EXPERIMENTAL
Intervention: MR-guided RF ablation
Number of subjects: 35

Group type: COMPARATOR
Intervention: CT-guided RF ablation
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both MR and CT-guided RF ablation
Number of subjects: 35
Study: 22112969

Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m2 day 1) and prednisone (5 mg orally twice daily every 21 days) plus AT-101 (40 mg twice daily on days 1-3)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m2 day 1) and prednisone (5 mg orally twice daily every 21 days) plus placebo
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Docetaxel plus prednisone with AT-101
Number of subjects: 221

Group type: COMPARATOR
Intervention: Docetaxel plus prednisone with placebo
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Docetaxel plus prednisone with AT-101 in high-risk mCRPC (n=34)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Docetaxel plus prednisone with placebo in high-risk mCRPC (n=34)
Number of subjects: 221
Study: 20940688

Group type: EXPERIMENTAL
Intervention: Information on anxiolytic technique, local anesthesia, and treatment of perioperative pain
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Preoperative visit information
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Loco-regional anesthesia
Number of subjects: 150
Study: 17438342

Group type: EXPERIMENTAL
Intervention: Behavioral treatment
Number of subjects: 25

Group type: COMPARATOR
Intervention: Eclectic treatment
Number of subjects: 25
Study: 15798963

Group type: EXPERIMENTAL
Intervention: Moderate to intense exercise training for 16 weeks
Number of subjects: 51

Group type: COMPARATOR
Intervention: No exercise training (control)
Number of subjects: 51
Study: 16678648

Group type: EXPERIMENTAL
Intervention: MAS XR 10 mg/d
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: MAS XR 20 mg/d
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: MAS XR 30 mg/d
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: MAS XR 40 mg/d
Number of subjects: 287

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 287